Whalesbook
Goldline Pharma IPO Soars on Debt Repayment Focus
Goldline Pharmaceutical's first public offering has been a major success. By May 13, its IPO was subscribed 93.19 times. Strong demand came from retail investors, who subscribed 139.51 times their quota, and non-institutional investors, who subscribed 108.19 times. The Rs 11.61 crore IPO, priced between Rs 41-43 per share, plans to use Rs 8.35 crore of the proceeds to repay borrowings. This focus on strengthening its balance sheet appears to resonate well with investors.
RFBL Flexi Pack Eyes Expansion
Meanwhile, RFBL Flexi Pack, a maker of printed multilayer flexible packaging materials, is raising Rs 35.33 crore through its IPO, priced at Rs 47-50 per share. The issue was subscribed 1.57 times by the second day. Proceeds are earmarked for growth, with Rs 12.4 crore for land acquisition and a new facility, and Rs 17.76 crore for working capital. This expansionary plan is generating more moderate investor interest compared to Goldline's debt repayment strategy.
Comparing Valuations and Business Models
Goldline Pharmaceutical uses an asset-light model, outsourcing manufacturing and focusing on marketing. Its FY25 revenue was Rs 28.06 crore with Rs 2.83 crore in profit (PAT), achieving a 35.83% return on equity (ROE). Post-IPO, its P/E ratio is expected around 15.19x, significantly lower than the Nifty Pharma index's P/E of 35.3 and peers like Sun Pharma (P/E 36.49). This valuation could be attractive, but investors should note its reliance on contract manufacturers and revenue concentration in Maharashtra and Madhya Pradesh (nearly 71%).
RFBL Flexi Pack reported robust FY25 revenue of Rs 135.46 crore and Rs 8.33 crore PAT. Its post-IPO P/E is also around 15.19x, aligning with packaging industry averages. RFBL shows strong return on net worth (RoNW) over 60% and return on capital employed (RoCE) of 32.70%. However, its Debt/Equity ratio stands at 0.80. A significant portion of its revenue (over 62% as of Nov 2025) comes from trading, which might mean lower margins than pure manufacturing.
IPO Market Trends and Risks
The IPO market in FY26 shows investors are favoring value over past exuberance. Average listing day gains have fallen to 8% from 28% last year, signaling increased focus on valuation and how companies use funds. While SME IPOs continue to see high subscriptions, caution is needed due to potential post-listing volatility.
Goldline Pharmaceutical's main risks include heavy reliance on third-party manufacturers and a concentrated distribution network. Its top customer accounts for 35.29% of revenue, and the top 10 customers make up 89.39%. Additionally, active tax proceedings totaling about Rs 3.34 crore present a potential future liability. Lower QIB subscription compared to retail may signal caution about these concentration and operational risks.
RFBL Flexi Pack's main risk is its leverage, with a Debt/Equity ratio of 0.80 higher than some peers. Significant revenue from trading, not just manufacturing, could also pressure margins and add business model volatility. Successful integration of its new facility and sustained profitability will be critical.
Outlook for Distinct Investment Cases
The IPO market remains active in FY26, supported by domestic liquidity and a preference for quality companies with solid fundamentals and clear growth plans. Goldline offers a deleveraging play with an asset-light model, while RFBL is an expansion play in the flexible packaging sector. Investors are increasingly prioritizing companies with strong balance sheets and clear capital use, a trend likely to shape these new listings' performance.